Particularly, SNX7 was linked with the AD condition, with authors highlighting that SNX7 decreases Aβ production by modulating APP cell surface levels [52] (Fig. 4D), as was SNX8, where SNPs have been linked with the risk of development of Late onset AD [214], being SNX8 also identified as an Aβ toxicity enhancer [118, 214] (Fig. 4d). Here, APP is linked to Alzheimer disease.